Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
Nisha S Joseph,1 Yu-Tzu Tai,2 Kenneth C Anderson,2 Sagar Lonial1 1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; 2Dana-Farber Cancer Institute, Harvard University, Boston, MA, USACorrespondence: Kenneth C AndersonDana-Farber Cancer Institute, Blood Compont, D289, 44...
Guardado en:
Autores principales: | Joseph NS, Tai YT, Anderson KC, Lonial S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0d721601a192472480532b05603dd0e1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials
por: Yali Tao, et al.
Publicado: (2021) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon N, et al.
Publicado: (2016) -
Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Chetan Rathi, et al.
Publicado: (2021) -
Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
por: Russell Sterrett, et al.
Publicado: (2021)